A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo

Human Antibodies

Volumn 19, Issue 4, 2010, Pages 113-128

  Ebert, Tim ^a   Smith, Sharon ^a   Pancari, Greg ^a   Clark, Desmond ^a   Hampton, Richard ^a   Secore, Susan ^a   Towne, Victoria ^a   Fan, Hongxia ^a   Wang, Xin Min ^a   Wu, Xiaoqing ^a   Ernst, Robin ^a   Harvey, Barrett R ^a   Finnefrock, Adam C ^a   Wang, Fubao ^a   Tan, Charles ^a   Durr, Eberhard ^a   Cope, Leslie ^a   Anderson, Annaliesa ^a   An, Zhiqiang ^a   McNeely, Tessie ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

biofilm; indwelling catheter model; iron regulated surface determinant; monoclonal antibody; rodent models; Staphylococcus; survival model

Indexed keywords

BACTERIAL PROTEIN; IRON REGULATED SURFACE DETERMINANT B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CS D7; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BINDING AFFINITY; BINDING SITE; CATHETER INFECTION; CENTRAL VENOUS CATHETERIZATION; CONTROLLED STUDY; DRUG ISOLATION; FEMALE; MOUSE; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; RAT; SEPSIS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BACTEREMIA; CATHETERIZATION, CENTRAL VENOUS; CATION TRANSPORT PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PHAGOCYTOSIS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78650586788     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2010-0235     Document Type: Article

References (41)

1. J.C. Lee, The prospects for developing a vaccine against Staphylococcus aureus, Trends inMicrobiology 4 (1996), 162-166.
2. J.R. Middleton, Staphylococcus aureus antigens and challenges in vaccine development, Expert Reviews 7 (2008), 805-815.
3. M. Otto, Targeted immunotherapy for staphylococcal infections Focus on anti-MSCRAMM antibodies, Biodrugs 22 (2008), 27-36.
4. A.C. Schaffer and J.C. Lee, Vaccination and passive immunisation against Staphylococcus aureus, International Journal of Antimicrobial Agents 32 (2008), S71-S78.
5. K.M. Cunnion, D.K. Benjamin, C.G. Hester and M.M. Frank, Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Stophylococcus aureus bacteremia, Journal of Laboratory and Clinical Medicine 143 (2004), 358-365.
6. S.H. Gregory, A.J. Sagnimeni and E.J. Wing, Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils, Journal of Immunology 157 (1996), 2514-2520.
7. M. Verdrengh and A. Tarkowski, Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus, Infection and Immunity 65 (1997), 2517-2521.
8. P.K. Peterson, B.J. Wilkinson, Y. Kim, D. Schmeling, S.D. Douglas, P.G.Quie and J. Verhoef, Key Role of Peptidoglycan in Opsonization of Staphylococcus-Aureus, Journal of Clinical Investigation 61 (1978), 597-609.
9. H.A. Verbrugh, P.K. Peterson, B.Y.T. Nguyen, S.P. Sisson and Y. Kim, Opsonization of Encapsulated Staphylococcus-Aureus the Role of Specific Antibody and Complement, Journal of Immunology 129 (1982), 1681-1687.
10. P.C.J. Leijh, M.T. Vandenbarselaar, M.R. Daha and R. Vanfurth, Participation of Immunoglobulins and Complement Components in the Intracellular Killing of Staphylococcus-Aureus and Escherichia-Coli by Human-Granulocytes, Infection and Immunity 33 (1981), 714-724.
11. S.K. Mazmanian, E.P. Skaar, A.H. Gaspar, M. Humayun, P. Gornicki, J. Jelenska, A. Joachmiak, D.M. Missiakas and O. Schneewind, Passage of hemeiron across the envelope of Staphylococcus aureus, Science 299 (2003), 906-909.
12. M. Brown, R. Kowalski, J. Zorman, X.M. Wang, V. Towne, Q.J. Zhao, S. Secore, A.C. Finnefrock, T. Ebert, G. Pancari, K. Isett, Y.H. Zhang, A.S. Anderson, D. Montgomery, L. Cope and T. McNeely, Selection and Characterization of Murine Monoclonal Antibodies to Staphylococcus aureus IronRegulated Surface Determinant B with Functional Activity In Vitro and In Vivo, Clinical and Vaccine Immunology 16 (2009), 1095-1104.
13. F.D. Lowy, Medical progress-Staphylococcus aureus infections, New England Journal ofMedicine 339 (1998), 520-532.
14. N.A. Kuklin, D.J. Clark, S. Secore, J. Cook, L.D. Cope, T. McNeely, L.Noble,M.J. Brown, J.K. Zorman, X.M.Wang, G. Pancari, H. Fan, K. Isett, B. Burgess, J. Bryan, M. Brownlow, H. George, M. Meinz, M.E. Liddell, R. Kelly, L. Schultz, D. Montgomery, J. Onishi, M. Losada, M. Martin, T. Ebert, C.Y. Tan, T.L. Schofield, E. Nagy, A. Meineke, J.G. Joyce, M.B. Kurtz, M.J. Caulfield, K.U. Jansen,W.McClements and A.S. Anderson, A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model, Infect Immun 74 (2006), 2215-2223.
15. Y.K. StrangerJones, T. Bae and O. Schneewind, Vaccine assembly from surface proteins of Staphylococcus aureus, Proc Natl Acad Sci U S A 103 (2006), 16942-16947.
16. H.K. Kim, A. DeDent, A.G. Cheng, M. McAdow, F. Bagnoli, D.M.Missiakas and O. Schneewind, IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge, Vaccine 28 (2010), 6382-6392. Ref Type: Journal (Full)
17. T.J. Vaughan, A.J.Williams, K. Pritchard, J.K. Osbourn, A.R. Pope, J.C. Earnshaw, J.McCafferty, R.A.Hodits, J.Wilton and K.S. Johnson,Human antibodieswith sub-nanomolar affinities isolated from a large non-immunized phage display library, Nature Biotechnology 14 (1996), 309-314.
18. L. Persic, A. Roberts, J. Wilton, A. Cattaneo, A. Bradbury and H.R. Hoogenboom, An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries, Gene 187 (1997), 9-18
19. M.D. Raedler, S. Heyne, E. Wagner, S.K. Shalkowski, S. Secore, A.S. Anderson, J. Cook, L. Cope, T. McNeely, M. Retzlaff, J. Shanter, L.J. Rubinstein, T. Green, N. Kartsonis and M.T. Esser, Serologic Assay To Quantify Human Immunoglobulin G Antibodies to the Staphylococcus aureus Iron Surface Determinant B Antigen, Clinical and Vaccine Immunology 16 (2009), 739-748.
20. J. Cook, R. Hepler, G. Pancari, N. Kuklin, H.X. Fan, X.M. Wang, L. Cope, C. Tan, J. Joyce, J. Onishi, D. Montgomery, A. Anderson and T. McNeely, Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy inmurine models of staphylococcal infection, Human Vaccines 5 (2009), 254-263.
21. C.P. Taborda, J. Rivera, O. Zaragoza and A. Casadevall, More is not necessarily better: Prozone-like effects in passive immunization with IgG, Journal of Immunology 170 (2003), 3621-3630.
22. R. Betts, C. Harro, M. Onorato, J. Hartzel, J. Lipka and N. Kartsonis, Immunogenicity & Safety of a Novel Staphylococcus aureus (SA) Vaccine (V710) Across Different Age Groups, Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 48 (2008), 342.
23. C. Harro, R. Betts, J. Lipka, J. Hartzel, M. Onorato and N. Kartsonis, Two Phase I, Multicenter, DoubleBlind Studies to Investigate Immunogenicity and Safety of Different Formulations of a Novel Staphylococcus aureus Vaccine (V710), Abstracts of the 13th International Symposium on Staphylococci and Staphylococcal Infections (2008).
24. A.I. Fattom, J. Sarwar, A.Ortiz andR.Naso, A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge, Infection and Immunity 64 (1996), 1659-1665.
25. J.H. Vernachio, A.S. Bayer, B. Ames, D. Bryant, B.D. Prater, P.J. Syribeys, E.L. Gorovits and J.M. Patti, Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo, Antimicrobial Agents and Chemotherapy 50 (2006), 511-518.
26. S.K. Mazmanian, H. Ton-That, K. Su and O. Schneewind, An ironregulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis, Proceedings of the National Academy of Sciences of the United States of America 99 (2002), 2293-2298. (Pubitemid 34169054)
27. H.Miajlovic, M. Zapotoczna, J.A.Geoghegan, S.W.Kerrigan, P. Speziale and T.J. Foster, Direct interaction of iron-regulated surface determinant IsdB of Staphylococcus aureus with the GPIIb/IIIa receptor on platelets, Microbiology 156 (2010), 920-928.
28. I. Gjertsson, O.H. Hultgren, M. Stenson, R. Holmdahl and A. Tarkowski, Are B lymphocytes of importance in severe Staphylococcus aureus infections? Infection and Immunity 68 (2000), 2431-2434.
29. I. Gjertsson, L. Nitschke and A. Tarkowski, The role of B cell CD22 expression in Staphylococcus aureus arthritis and sepsis, Microbes and Infection 6 (2004), 377-382.
30. D.S. Fedson, The clinical effectiveness of pneumococcal vaccination: a brief review, Vaccine 17 (1999), S85-S90.
31. J.D.Wenger, R. Booy, P.T.Heath andR.Moxon, Epidemiological impact of conjugate vaccines on invasive disease caused by Haemophilus influenzae Type b. In Levine MM,Woodrow GC, Kaper JB, Cobon GS (eds): New Generation Vaccines, 2nd ed., revised and expanded, New York, NY, Marcel Dekker, Inc (1997).
32. Y. Minegishi and H. Karasuyama, Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency, International Immunology 21 (2009), 105-112.
33. Y. Minegishi, M. Saito, M. Nagasawa, H. Takada, T. Hara, S. Tsuchiya, K. Agematsu, M. Yamada, N. Kawamura, T. Ariga, I. Tsuge and H. Karasuyama, Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome, Journal of Experimental Medicine 206 (2009), 1291-1301.
34. O.C. Bruton, Agammaglobulinemia, Pediatrics 9 (1952), 722-728.
35. J.A. Winkelstein, M.C. Marino, H.M. Lederman, S.M. Jones, K. Sullivan, A.W. Burks, M.E. Conley, C. CunninghamRundles and H.D.Ochs, X-linked Agammaglobulinemia Report on a United States registry of 201 patients, Medicine 85 (2006), 193-202.
36. A.I. Fattom, G. Horwith, S. Fuller, M. Propst and R. Naso, Development of StaphVAX (TM), a polysaccharide conjugate vaccine against S-aureus infection: from the lab bench to phase III clinical trials, Vaccine 22 (2004), 880-887.
37. J.M. Patti, A humanized monoclonal antibody targeting Staphylococcus aureus, Vaccine 22 (2004), S39-S43.
38. J.P. Burnie, R.C. Matthews, T. Carter, E. Beaulieu, M. Donohoe, C. Chapman, P.Williamson and S.J. Hodgetts, Identification of an immunodominant ABC transporter in methicillinresistant Staphylococcus aureus infections, Infection and Immunity 68 (2000), 3200-3209.
39. M.E. Rupp, H.P. Holley, J. Lutz, P.V. Dicpinigaitis, C.W. Woods, D.P. Levine, N. Veney and V.G. Fowler, Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia, Antimicrobial Agents and Chemotherapy 51 (2007) 4249-4254.
40. M. Dejonge, D. Burchfield, B. Bloom, M. Duenas, W. Walker, M. Polak, F. Jung, D. Millard, R. Schelonka, F. Eyal, A. Morris, B. Kapik, D. Roberson, K. Kesler, J. Patti and S. Hetherington, Clinical trial of safety and efficacy of IHN-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants, Journal of Pediatrics 151 (2007), 260-265.
41. J.J.Weems, J.P. Steinberg, S. Filler, J.W. Baddley, G.R. Corey, P. Sampathkumar, L. Winston, J.F. John, C.J. Kubin, R. Talwani, T. Moore, J.M. Patti, S. Hetherington, M. Texter, E. Wenzel, V.A. Kelley and V.G. Fowler, Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia, Antimicrobial Agents and Chemotherapy 50 (2006) 2751-2755.